Equetro is a drug owned by Validus Pharmaceuticals Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 19, 2024. Details of Equetro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6977253 | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(11 months ago) |
Expired
|
| US5912013 | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
Jun, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Equetro's patents.
Latest Legal Activities on Equetro's Patents
Given below is the list of recent legal activities going on the following patents of Equetro.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) Critical | 23 Jul, 2010 | US6977253 (Litigated) |
| Correspondence Address Change Critical | 22 Jul, 2010 | US6977253 (Litigated) |
| Mail Pre-Exam Notice | 25 Jun, 2010 | US6977253 (Litigated) |
| Correspondence Address Change Critical | 24 Jun, 2010 | US6977253 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Dec, 2007 | US6977253 (Litigated) |
| Correspondence Address Change Critical | 03 Dec, 2007 | US6977253 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 20 Dec, 2005 | US6977253 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 20 Dec, 2005 | US6977253 (Litigated) |
| Issue Notification Mailed Critical | 30 Nov, 2005 | US6977253 (Litigated) |
| Dispatch to FDC | 18 Nov, 2005 | US6977253 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Equetro is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Equetro's family patents as well as insights into ongoing legal events on those patents.
Equetro's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Equetro's generic launch date based on the expiry of its last outstanding patent is estimated to be May 19, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Equetro Generic API suppliers:
Carbamazepine is the generic name for the brand Equetro. 33 different companies have already filed for the generic of Equetro, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Equetro's generic
How can I launch a generic of Equetro before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Equetro's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Equetro's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Equetro -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 200 mg and 300 mg | 21 Aug, 2007 | 1 | 19 May, 2024 | Extinguished | |
| 100 mg | 23 May, 2014 | 1 | 19 May, 2024 | Extinguished |
Alternative Brands for Equetro
Equetro which is used for treating bipolar disorder., has several other brand drugs using the same active ingredient (Carbamazepine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Carbamazepine, Equetro's active ingredient. Check the complete list of approved generic manufacturers for Equetro
About Equetro
Equetro is a drug owned by Validus Pharmaceuticals Llc. It is used for treating bipolar disorder. Equetro uses Carbamazepine as an active ingredient. Equetro was launched by Validus Pharms in 2004.
Approval Date:
Equetro was approved by FDA for market use on 10 December, 2004.
Active Ingredient:
Equetro uses Carbamazepine as the active ingredient. Check out other Drugs and Companies using Carbamazepine ingredient
Treatment:
Equetro is used for treating bipolar disorder.
Dosage:
Equetro is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 100MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 200MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |